MAPT and dementia: Tau is measured using CSF levels of phosphorylated tau or PET with ligands binding to tau and neurodegeneration is measured using MRI, fluorodeoxyglucose-PET or CSF total tau.5 6 However, such biomarkers are challenging to apply at scale, or frequently, and also need evidence of their performance and differences across multiple dementias.